Table of Contents
Journal of Vaccines
Volume 2015, Article ID 869468, 7 pages
http://dx.doi.org/10.1155/2015/869468
Review Article

Identifying and Overcoming Perceived Barriers of Providers towards HPV Vaccination: A Literature Review

Creighton University, 2500 California Plaza, Omaha, NE 68178, USA

Received 31 August 2015; Revised 12 November 2015; Accepted 19 November 2015

Academic Editor: Itabajara da Silva Vaz Jr

Copyright © 2015 Jessica Palmer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. E. Markowitz, E. F. Dunne, M. Saraiya et al., “Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP),” Morbidity and Mortality Weekly Report, vol. 63, no. RR05, pp. 1–30, 2014, http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6305a1.htm. View at Google Scholar
  2. CDC, Human Papillomavirus (HPV)-Associated Cancers, CDC, 2014, http://www.cdc.gov/cancer/hpv/statistics/cases.htm.
  3. NCI, Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer. A Report to the President of the United States from the President's Cancer Panel, National Cancer Institute, Bethesda, Md, USA, 2014.
  4. A. K. Chaturvedi, E. A. Engels, R. M. Pfeiffer et al., “Human papillomavirus and rising oropharyngeal cancer incidence in the United States,” Journal of Clinical Oncology, vol. 29, no. 32, pp. 4294–4301, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. CDC, Human Papillomavirus. The Pink Book: Course Textbook, Second Printing, CDC, 12th edition, 2012, http://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html.
  6. H. W. Chesson, D. U. Ekwueme, M. Saraiya, M. Watson, D. R. Lowy, and L. E. Markowitz, “Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States,” Vaccine, vol. 30, no. 42, pp. 6016–6019, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Petrosky, J. A. Bocchini, S. Hariri et al., “Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices,” Morbidity and Mortality Weekly Report, vol. 64, no. 11, pp. 300–304, 2015. View at Google Scholar
  8. L. D. Elam-Evans, D. Yankey, J. Jeyarajah et al., “National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years-United States, 2013,” Morbidity and Mortality Weekly Report, vol. 63, no. 29, pp. 625–633, 2014. View at Google Scholar
  9. M. B. Gilkey, J. L. Moss, A.-L. McRee, and N. T. Brewer, “Do correlates of HPV vaccine initiation differ between adolescent boys and girls?” Vaccine, vol. 30, no. 41, pp. 5928–5934, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Stokley, J. Jeyarajah, D. Yankey et al., “Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014-United States,” Morbidity and Mortality Weekly Report, vol. 63, no. 29, pp. 620–624, 2014. View at Google Scholar · View at Scopus
  11. C. A. Wong, J. A. Taylor, J. A. Wright, D. J. Opel, and R. A. Katzenellenbogen, “Missed opportunities for adolescent vaccination, 2006–2011,” Journal of Adolescent Health, vol. 53, no. 4, pp. 492–497, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. AAP, “Give a strong recommendation for HPV vaccine to increase uptake!,” April 2014, http://www2.aap.org/immunization/illnesses/hpv/hpv.html.
  13. US Department of Health and Human Services, Health People 2020. Healthy People 2020 Topics and Objectives, 2014, http://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases.
  14. A. G. Litton, R. A. Desmond, J. Gilliland, W. K. Huh, and F. A. Franklin, “Factors associated with intention to vaccinate a daughter against HPV: a statewide survey in Alabama,” Journal of Pediatric & Adolescent Gynecology, vol. 24, no. 3, pp. 166–171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. R. B. Perkins, J. A. Clark, G. Apte et al., “Missed opportunities for HPV vaccination in adolescent girls: a qualitative study,” Pediatrics, vol. 134, no. 3, pp. e666–e674, 2014. View at Google Scholar
  16. K. R. Ylitalo, H. Lee, and N. K. Mehta, “Health care provider recommendation, human papillomavirus vaccination, and Race/Ethnicity in the US national immunization survey,” American Journal of Public Health, vol. 103, no. 1, pp. 164–169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. M. A. Allison, E. F. Dunne, L. E. Markowitz et al., “HPV vaccination of boys in primary care practices,” Academic Pediatrics, vol. 13, no. 5, pp. 466–474, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. M. F. Daley, L. A. Crane, L. E. Markowitz et al., “Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure,” Pediatrics, vol. 126, no. 3, pp. 425–433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. C. C. Jim, J. Wai-Yin Lee, A. V. Groom et al., “Human papillomavirus vaccination practices among providers in Indian health service, tribal and urban Indian healthcare facilities,” Journal of Women's Health, vol. 21, no. 4, pp. 372–378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Saraiya, J. I. Rosser, and C. P. Cooper, “Cancers that U.S. physicians believe the HPV vaccine prevents: findings from a physician survey, 2009,” Journal of Women's Health, vol. 21, no. 2, pp. 111–117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. C. C. Hughes, A. L. Jones, K. A. Feemster, and A. G. Fiks, “HPV vaccine decision making in pediatric primary care: a semi-structured interview study,” BMC Pediatrics, vol. 11, article 74, pp. 1–9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Gowda, S. E. Schaffer, K. J. Dombkowski, and A. F. Dempsey, “Understanding attitudes toward adolescent vaccination and the decision-making dynamic among adolescents, parents and providers,” BMC Public Health, vol. 12, article 509, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. L. M. Kester, G. D. Zimet, J. D. Fortenberry, J. A. Kahn, and M. L. Shew, “A national study of HPV vaccination of adolescent girls: rates, predictors, and reasons for non-vaccination,” Maternal and Child Health Journal, vol. 17, no. 5, pp. 879–885, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. E. L. McCave, “Influential factors in HPV vaccination uptake among providers in four States,” Journal of Community Health, vol. 35, no. 6, pp. 645–652, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. J. A. Kahn, H. P. Cooper, S. T. Vadaparampil et al., “Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to-12-year-old girls: a statewide survey of Texas physicians,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 8, pp. 2325–2332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. R. B. Perkins and J. A. Clark, “What affects human papillomavirus vaccination rates? A qualitative analysis of providers' perceptions,” Women's Health Issues, vol. 22, no. 4, pp. e379–e386, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. J. L. Moss, A. L. Feld, B. O'Malley et al., “Opportunities for increasing human papillomavirus vaccine provision in school health centers,” Journal of School Health, vol. 84, no. 6, pp. 370–378, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. US Department of Health and Human Services, Health Resources and Services Administration, 2015, http://www.hrsa.gov/ourstories/schoolhealthcenters.
  29. N. T. Brewer, J. K. Chung, H. M. Baker, M. C. Rothholz, and J. S. Smith, “Pharmacist authority to provide HPV vaccine: novel partners in cervical cancer prevention,” Gynecologic Oncology, vol. 132, supplement 1, pp. S3–S8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. CDC, “FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardisil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP),” Morbidity and Mortality Weekly Report, vol. 59, no. 20, pp. 630–632, 2010. View at Google Scholar
  31. CDC, “FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP),” Morbidity and Mortality Weekly Report, vol. 59, no. 20, pp. 626–629, 2010. View at Google Scholar
  32. A. S. Noronha, L. E. Markowitz, and E. F. Dunne, “Systematic review of human papillomavirus vaccine coadministration,” Vaccine, vol. 32, no. 23, pp. 2670–2674, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. N. P. Klein, J. Hansen, C. Chao et al., “Safety of quadrivalent human papillomavirus vaccine administered routinely to females,” Archives of Pediatrics and Adolescent Medicine, vol. 166, no. 12, pp. 1140–1148, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. P. S. Sow, D. Watson-Jones, N. Kiviat et al., “Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10–25-year-old HIV-seronegative African girls and young women,” The Journal of Infectious Diseases, vol. 207, no. 11, pp. 1753–1763, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. FDA, “Highlights of prescribing information. Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant),” 2014, http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm426520.htm.
  36. E. A. Joura, A. R. Giuliano, O.-E. Iversen et al., “A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women,” The New England Journal of Medicine, vol. 372, no. 8, pp. 711–723, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. FDA, Product approval-prescribing information (package insert). Cervarix[human papillomavirus bivalent (types 16 and 18) vaccine, recombinant], GlaxoSmithKline Biologicals, FDA, 2009, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf.
  38. J. Gee, A. Naleway, I. Shui et al., “Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink,” Vaccine, vol. 29, no. 46, pp. 8279–8284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. S. T. Vadaparampil, J. A. Kahn, D. Salmon et al., “Missed clinical opportunities: provider recommendations for HPV vaccination for 11-12 year old girls are limited,” Vaccine, vol. 29, no. 47, pp. 8634–8641, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. U.S. Department of Health and Human Services, “The affordable care act and immunization,” August 2015, http://www.hhs.gov/healthcare/facts/factsheets/2010/09/The-Affordable-Care-Act-and-Immunization.html.
  41. R. Gold, A. Naleway, and K. Riedlinger, “Factors predicting completion of the human papillomavirus vaccine series,” Journal of Adolescent Health, vol. 52, no. 4, pp. 427–432, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. Merck & Co Inc, MerkVaccines.com: Professional Resources, Support, & More, 2014, https://www.merckvaccines.com/Professional-Resources/Pages/ProfessionalResourcesHome?WT.svl=5.
  43. S. G. Federico, L. Abrams, R. M. Everhart, P. Melinkovich, and S. J. Hambidge, “Addressing adolescent immunization disparities: a retrospective analysis of school-based health center immunization delivery,” American Journal of Public Health, vol. 100, no. 9, pp. 1630–1634, 2010. View at Publisher · View at Google Scholar · View at Scopus